Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic

B Blasco, D Leroy, DA Fidock - Nature medicine, 2017 - nature.com
The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s
heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria …

Antimalarial drug resistance: a threat to malaria elimination

D Menard, A Dondorp - Cold Spring …, 2017 - perspectivesinmedicine.cshlp.org
Increasing antimalarial drug resistance once again threatens effective antimalarial drug
treatment, malaria control, and elimination. Artemisinin combination therapies (ACTs) are …

Catalytic Reactions and Energy Conservation in the Cytochrome bc1 and b6f Complexes of Energy-Transducing Membranes

M Sarewicz, S Pintscher, R Pietras, A Borek… - Chemical …, 2021 - ACS Publications
This review focuses on key components of respiratory and photosynthetic energy-
transduction systems: the cytochrome bc 1 and b 6 f (Cyt bc 1/b 6 f) membranous …

Antimalarial application of quinones: A recent update

OPS Patel, RM Beteck, LJ Legoabe - European Journal of Medicinal …, 2021 - Elsevier
Atovaquone belongs to a naphthoquinone class of drugs and is used in combination with
proguanil (Malarone) for the treatment of acute, uncomplicated malaria caused by …

Comprehensive review on various strategies for antimalarial drug discovery

M Mishra, VK Mishra, V Kashaw, AK Iyer… - European journal of …, 2017 - Elsevier
The resistance of malaria parasites to existing drugs carries on growing and progressively
limiting our ability to manage this severe disease and finally lead to a massive global health …

Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes

CD Goodman, JE Siregar, V Mollard… - Science, 2016 - science.org
Drug resistance compromises control of malaria. Here, we show that resistance to a
commonly used antimalarial medication, atovaquone, is apparently unable to spread …

[HTML][HTML] Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

JS McCarthy, J Lotharius, T Rückle… - The Lancet Infectious …, 2017 - thelancet.com
Background DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate
dehydrogenase, an enzyme essential for pyrimidine biosynthesis. We investigated the …

In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19

C Sachdeva, A Wadhwa, A Kumari… - OMICS: A Journal of …, 2020 - liebertpub.com
Although the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is wreaking havoc and resulting in …

Recent advances in use of silver nanoparticles as antimalarial agents

M Rai, AP Ingle, P Paralikar, I Gupta, S Medici… - International Journal of …, 2017 - Elsevier
Malaria is one of the most common infectious diseases, which has become a great public
health problem all over the world. Ineffectiveness of available antimalarial treatment is the …

[HTML][HTML] Functional and biochemical characterization of the Toxoplasma gondii succinate dehydrogenase complex

MF Silva, K Douglas, S Sandalli, AE Maclean… - PLoS …, 2023 - journals.plos.org
The mitochondrial electron transport chain (mETC) is a series of membrane embedded
enzymatic complexes critical for energy conversion and mitochondrial metabolism. In …